1-3 of 3
Andras Rosta, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study

Joseph M Connors, MD, Wojciech Jurczak, PhDMD, David J. Straus, MD, Stephen M Ansell, MD PhD, Won Seog Kim, MD, Ph. D., Andrea Gallamini, MD, Anas Younes, MD, Sergei Alekseev, PhD, Arpad Illes, MD, Marco Picardi, Ewa Lech-Maranda, MDPhD, Yasuhiro Oki, MD, Tatyana A Feldman, MD, Piotr Smolewski, MD PhD, Kerry J Savage, BSc, MD MSc, Nancy L. Bartlett, MD, Jan Walewski, MD PhD, Robert W. Chen, MD, Rod Ramchandren, MD, Pier Luigi Zinzani, MD, David Cunningham, MD FRCP, Dae Seog Heo, MD, Andras Rosta, MD, Neil Josephson, MD, Katherine L. Ruffner, MD, Jessica Sachs, Rachael Liu, PhD, Hina Jolin, Pharm D, Dirk Huebner, MD, John A. Radford, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 6.
https://doi.org/10.1182/blood.V130.Suppl_1.6.6
Published: 2017
Journal Articles

Immunochemotherapy As Induction (R-CHOP and R-HyperC-VAD/R-MA) in Mantle Cell Lymphoma, a Hungarian Multicenter Open Label Phase II Study (Rituximab [MabThera®] in Mantle Cell Lymphoma, REMENY)

Miklos Udvardy, MD, PhD, Andras Rosta, MD, PhD, Zoltan Gasztonyi, MD, Zita Borbenyi, MD, PhD, Gaspar Radvanyi, MD, Miklos Egyed, MD, PhD, Beata Gasztonyi, MD, PhD, Hajna Losonczy, MD, PhD, Andras Matolcsy, MD, PhD, Agnes H. Andrasfalvy, MD, Tamas J. Schneider, MD
Journal: Blood
Blood (2012) 120 (21): 4889.
https://doi.org/10.1182/blood.V120.21.4889.4889
Published: 2012
Journal Articles

Results of the Interim Analysis of the “HUSOM” Trial: Hungarian Study of Maintenance After Rituximab Pretreatment, A Multicentre, Phase III, Open-Label Study Evaluating the Benefit of a Long-Term MabThera (rituximab) Maintenance Therapy in Patients with Advance Follicular Lymphoma After Induction of Response (CR(u) or PR) with a MabThera (rituximab)-Containing First Line Regimen

Tamas J. Schneider, MD, Andras Rosta, MD, PhD, Hajna Losonczy, MD, PhD, Gaspar Radvanyi, MD, Gyorgy Ujj, MD, Arpad Illes, MD, PhD, János Jakucs, MD, Zita Borbenyi, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2714.
https://doi.org/10.1182/blood.V118.21.2714.2714
Published: 2011